

**C B G**

---

*M E B*

**College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board**

**Graadt van Roggenweg 500  
3531 AH Utrecht  
The Netherlands**

**MUTUAL RECOGNITION PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT**

**Hippomectin 12 mg/g oral gel for horses**

**Created: May 2022**

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

## MODULE 1

### PRODUCT SUMMARY

EU Procedure number	NL/V/0132/001/MR
Name, strength and pharmaceutical form	Hippomectin 12 mg/g oral gel
Applicant	Le Vet B.V. Wilgenweg 7 3421 TV Oudewater The Netherlands
Active substance(s)	Ivermectine
ATC Vetcode	QP54AA01
Target species	Horses
Indication for use	<p>The product is indicated for the treatment of parasitic infestations in horses due to:</p> <p><b>Large strongyles</b>  <i>Strongylus vulgaris</i> (adults and arterial larval stages)  <i>S. edentatus</i> (adults &amp; tissue larval stages)  <i>S. equinus</i> (adults)  <i>Triodontophorus</i> spp. (adults)  <i>Triodontophorus brevicauda</i>  <i>Triodontophorus serratus</i>  <i>Craterostomum acuticaudatum</i>, (adults)</p> <p><b>Small Strongyles</b> (adult and fourth stage larvae including benzimidazole-resistant strains)  <i>Coronocyclus</i> spp  <i>Coronocyclus coronatus</i>  <i>Coronocyclus labiatus</i>  <i>Coronocyclus labratus</i>  <i>Cyathostomum</i> spp  <i>Cyathostomum catinatum</i>  <i>Cyathostomum pateratum</i>  <i>Cylicocyclis</i> spp  <i>Cylicocyclis ashworthi</i>  <i>Cylicocyclis elongatus</i>  <i>Cylicocyclis insigne</i>  <i>Cylicocyclis leptostomum</i>  <i>Cylicocyclis nassatus</i>  <i>Cylicocyclis radiatus</i>  <i>Cylicostephanus</i> spp  <i>Cylicostephanus asymmetricus</i>  <i>Cylicostephanus bidentatus</i></p>

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

	<p> <i>Cylicostephanus calicatus</i>  <i>Cylicostephanus goldi</i>  <i>Cylicostephanus longibursatus</i>  <i>Cylicostephanus minutus</i>  <i>Cylicodontophorus</i> spp  <i>Cylicodontophorus bicornatus</i>  <i>Gyalocephalus capitatus</i>  <i>Parapoteriostomum</i> spp  <i>Parapoteriostomum euproctus</i>  <i>Parapoteriostomum mettami</i>  <i>Petrovinema</i> spp  <i>Petrovinema poculatum</i>  <i>Poteriostomum</i> spp  <i>Poteriostomum imparidentatum</i> </p> <p><b>Pinworms</b> (adult and L4 stages)  <i>Oxyuris equi</i></p> <p><b>Ascarids</b> (adult stages)  <i>Parascaris equorum</i></p> <p><b>Stomach worms</b> (adults stages)  <i>Trichostrongylus axei</i>, <i>Habronema muscae</i></p> <p><b>Intestinal threadworms</b> (adult stages)  <i>Strongyloides westeri</i></p> <p><b>Skin nematodes</b> (microfilariae)  <i>Onchocerca</i> sp.</p> <p><b>Stomach bots</b> (all larval stages)  <i>Gasterophilus</i> spp.</p> <p><b>Lungworms</b> (adult and L4 stages)  <i>Dictyocaulus arnfieldi</i></p>
--	--

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (<http://www.HMA.eu>).

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	29 October 2008
Date product first authorised in the Reference Member State (MRP only)	20 May 1992
Concerned Member States for original procedure	DE, ES, FI, FR, IT

#### I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

The reference product of this hybrid application is Eqvalan, which is registered in the Netherlands since 1992 with marketing authorisation number REG NL 1769. The initial application for Eqvalan was assessed before there was a requirement to have a public assessment report.

#### II. QUALITY ASPECTS

##### **A. Qualitative and quantitative particulars**

The product contains 120 mg Ivermectine per syringe and the excipients hydroxyethylcellulose, anise oil and propylene glycol.

The container/closure system consists of syringes containing 10 g each (equivalent to 10 doses). The syringes are consisting of a linear polyethylene piston, a LDPE barrel and closing cap and a polypropylene screw ring.

The choice of the formulation is justified.

The product is established pharmaceutical form and its development is considered a standard process.

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

## ***B. Method of Preparation of the Product***

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

## ***C. Control of Starting Materials***

The active substance is ivermectin, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

## ***D. Control on intermediate products***

Not applicable.

## ***E. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

## ***F. Stability***

The active substance is fully tested to ensure compliance with its specification immediately prior to its use in manufacture of the product.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 8 week stability after broaching is based on the demonstration of stability for a batch broached and stored 56 days at 25°C/60%RH.

## ***G. Other Information***

None.

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

### III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a hybrid application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

The pharmacological and toxicological aspects of this product are identical to the reference product.

#### III.A Safety Testing

##### User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that the product may cause eye irritation, skin sensitization and contact dermatitis.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

##### Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

#### Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product is intended to be used in a minor species that is reared and treated similarly to a major species for which an ERA already exists.

#### III.B Residues documentation

##### Residue Studies

Residue depletion studies using the final formulation have been conducted in horses. Samples of liver, kidney, muscle (hindquarter) and fat (abdominal) were taken from animals on day 18 after treatment. Results show that residues depleted to below the MRL in all tissues before the end of the withdrawal period.

##### MRLs

Ivermectin is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues
Ivermectin	22:23-Dihydroivermectin B1a	All mammalian food producing species	30 µg/kg 100 µg/kg 100 µg/kg 30 µg/kg	Muscle Fat Liver Kidney

Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

### ***Withdrawal Periods***

Based on the data provided above, a withdrawal period of 18 days for meat and offal in horses is justified. The product is not permitted for use in mares producing milk for human consumption.

## **IV. CLINICAL ASSESSMENT (EFFICACY)**

As this is a hybrid application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

## **V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.



Hippomectin 12 mg/g oral gel for horses	NL/V/0132/001/MR
Le Vet B.V.	MRP
	Publicly available assessment report

## MODULE 4

### POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website ([www.HMA.eu](http://www.HMA.eu)).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change	Section updated	Approval date
Change the name of the veterinary medicinal product in the CMS's Italy and Spain from Hippomectin to Vectimax. (NL/V/0132/001/IB/001)	NA	27 December 2009
Change in the address of the marketing authorisation holder. (NL/V/xxxx/IA/002/G)	Module 1, SPC	30 March 2011
Renewal (NL/V/0132/001/R/001)	NA	24 March 2015
Addition of a larger applicator to facilitate administration in horses up to 800 kg. (NL/V/0132/IB/003/G)	SPC	10 October 2014
Introduction of a new pharmacovigilance system. (NL/V/xxxx/WS/022)	NA	24 July 2019